Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Monthly Archives: December 2012

FDA Approves Aegerion’s lomitapide (Juxtapid) for Homozygous Familial Hypercholesterolemia

Tweet  In our November 20, 2012 article on this blog, entitled “Novel hypercholesterolemia drugs move toward FDA decisions”, we discussed two drugs–Aegerion Pharmaceuticals’ lomitapide, and Isis/Sanofi/Genzyme’s mipomersen. In October 2012, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommended that both drugs be approved for treatment of homozygous familial hypercholesterolemia (HoFH). In that article, we…

Haberman Associates in Chemical & Engineering News (C&EN) article on Agios Pharmaceuticals

Tweet  I was quoted in an article in the November 19, 2012 issue of Chemical & Engineering News (C&EN) by senior editor Lisa M Jarvis. The article is entitled “Agios Takes A Long View In Cell Metabolism.” The article focuses on Agios Pharmaceuticals’ (Cambridge, MA) strategy for building a company that can endure as an…

What is Haberman Associates?

Tweet A few weeks ago, I attended a presentation that was produced by another consulting firm, which we shall call Company X. They began their presentation with a discussion of “what is Company X?” Then they went on the the substance of their presentation. In the same vein, as the producers of the Biopharmconsortium Blog,…